Teva Targets Roche’s Rituxan in Drug Trial
Teva Pharmaceutical Industries is testing a copy of Roche Holding AG’s second-biggest-selling drug Rituxan.
This may be the first U.S. generic version of a monoclonal antibody, a protein-based medicine used to treat diseases ranging from arthritis to cancer. Teva this month began recruiting patients with rheumatoid arthritis for a clinical trial comparing its biosimilar copy, TL011, with the Roche drug, sold outside the U.S. as MabThera
Source: Bloomberg
